Search

Your search keyword '"A. Al Ghuzlan"' showing total 589 results
Start Over Author "A. Al Ghuzlan"
589 results on '"A. Al Ghuzlan"'

4. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

Author

Abdallah, A, Abentroth, AL, Acheimastos, V, Agunaoun, M, Al Bisher, HM, Al Ghuzlan, A, Alakus, H, Alkan, M, Almaraz Almaraz, MC, Amram, K, Anesidis, S, Anestiadou, E, Angelucci, D, Ansaldo, GL, Antonopoulou, MI, Arciniegas, M, Armellin, C, Arredondo Saldaña, G, Astl, J, Athanasakis, E, Avenia, S, Aydın, H, Baba, B, Babala, J, Banús, MV, Barba-Valadez, LA, Barcons, SV, Battafarano, F, Bayat, A, Bella, RMC, Benariba, F, Bernardi, S, Bignami, EG, Bitenc, M, Bitsianis, S, Bolaños de la Torre, JDD, Bonati, E, Bonetti, T, Borges, FA, Bouchagier, K, Boudina, M, Bourial, A, Breuskin, I, Brock, P, Bruns, C, Burlacu, MC, Burton, T, Buta, M, Buzanakov, D, Caliseo, C, Callanan, D, Calu, V, Cameselle-Teijeiro, JM, Camilo-Junior, DJ, Canberk, S, Candalise, V, Candanedo-Gonzalez, F, Carrillo Lizarazo, LJ, Carvalho, GB, Casallas, D, Casolino, C, Castellani, L, Castillo Morales, C, Chambon, G, Chatzipavlidou, V, Chernikov, R, Chorti, A, Chow, TCM, Chrisoulidou, A, Chrysos, E, Conrado-Neto, S, Cordova García, D, Corigliano, A, Crocco, A, Cuesta, A, Čukman, M, Curto, LS, Damilano, RA, D'Anna, R, De, M, De Virgilio, A, Dellaportas, D, Demarquet, L, Devresse, A, Di Meo, G, Diaz Pedrero, R, Dimitrov, D, Dmitry, Z, Domínguez Garijo, P, Dulgeroglu, O, Dural, AC, Eksi, A, El Hammoumi, M, El Kaoui, H, Eleni, G, Elliyanti, A, Ersöz, Ş, Escobar-Jiménez, M, Fedorova, L, Feeley, L, Fernández Rodríguez, E, Ferreli, F, Filoia, A, Fingeret, A, Francescato, A, Gaino, F, Galiandro, F, Gallegos-Hernández, JF, Garas, G, García Lorenzo, F, García-Chávez, JP, Gaudiello, M, Gay, S, Gerasimos, S, Gerek, M, Gervasi, R, Giordano, A, Gjeloshi, B, Gocký, L, Golubinskaya, E, González Romero, S, González-Mínguez, C, Goran, M, Gosman, A, Granados Garcia, M, Greco, E, Grünbart, M, Grützmann, R, Guerlain, J, Guirao, XG, Guzey, D, Hajjij, A, Hamdy, O, Hameed, MS, Hauth, LA, Hernández-Acevedo, JD, Hernandez-Carrillo, JF, Hevilla Sánchez, F, Hoi, H, Hongkwon, K, Hu Zhu, R, Huang, E, Hyeung Kyoo, K, Ignjatovic, V, Ioannidis, A, Iossa, A, Işık, A, James, D, Jung Hoon, L, Kara, H, Karajovic, J, Kartini, D, Khambri, D, Kholová, I, Kisiel, M, Knežević, M, Koh, YQ, Konca, C, Kosmidis, C, Kotsovolis, G, Kowalski, LP, Kralik, R, Kuczma, P, Kuravi, BG, Kurnia, A, Kyriaki, V, Lai, CM, Lallemant, B, Lardhi, AA, Leboulleux, S, Lee, JW, Lelli, G, Leutner, M, Lim, MY, Lim, CM, Llanos, A, Lo, X, Loderer, T, López-Corrales, MA, Ludwig, M, Magnabosco, FF, Maheo, C, Maia, AL, Makay, O, Maksimova, P, Mallick, S, Mallouk, C, Mamani, Z, Mandal, S, Manyalich Blasi, M, Marincola, G, Marulanda, M, Mavromati, M, Mayilvaganan, S, Metso, S, Micalizzi, A, Michalopoulos, A, Min-Su, K, Miron, A, Mishra, AK, Misso, C, Mittermair, C, Morosán Allo, Y, Mourad, M, Moysidis, M, Nabhan, F, Nasiri, R, Nastos, C, Ngiam, KY, Nomine-Criqui, C, Ntziovara, AM, Nuño Vázquez-Garza, JM, Nutautiene, V, Obtulovičová, K, O'Keeffe, L, Okudur, NO, Ossola, P, Ovejero Merino, E, Ozdemir, M, Pangonis, A, Panigoro, SS, Panuzi, A, Papaconstantinou, D, Pardo Matamoros, N, Paschou, S, Pasculli, A, Paterakis, K, Peiris, K, Pennestrì, F, Peppa, M, Perdikaris, P, Perdikaris, I, Pérez-Soto, RH, Piana, S, Piccoli, M, Pietrasanta, D, Placentino, G, Pliakos, I, Polistena, A, Pongtippan, A, Potard, G, Quinn, V, Rahul, P, Ramos, T, Rankin, A, Ratnayake, P, Reuto-Castillo, J, Ridolfo, A, Rios-Valencia, J, Riss, P, Rival, E, Rivillas, J, Roi, D, Rollo, EM, Romanchishen, A, Romito, M, Rotnagl, J, Rovcanin, B, Russo, G, Sabol, M, Saki, S, Saleh, S, Salih, A, Saltiki, A, Salvador-Camarmo, G, Samal, DK, Sánchez-Flores, S, Sapalidis, K, Sarin, D, Sarin, H, Savkovic, N, Scheffel, RS, Scheinpflug, AL, Scheuba, C, Scheyer, N, Schmidt, M, Senashova, O, Serafini, E, Serrano Arévalo, ML, Shank, J, Shindo, ML, Shoshkova, M, Shvan, M, Sičák, M, Silva, TG, Simó Guerrero, O, Skuletic, V, Slijepcevic, N, Slovic, Z, Soares, P, Somova, A, Soto, S, Spiezia, S, Stankovic, V, Stephenson, KJ, Straub, E, Summa, M, Surani, S, Syed, AA, Symeonidis, S, Taciak, A, Tarallo, M, Tarle, A, Tasis, N, Tausanovic, K, Tchabashvili, L, Thierry, M, Tokarczyk, U, Toma, EA, Topuz, S, Torresan, F, Uras, C, Vaccaro, C, Valdés de Anca, Á, Valentini, M, Varaldo, E, Vartanian, JG, Verras, GI, Vithanage, A, Wijayalathge, H, Wiriyaamornchai, P, Wong, YLC, Wongwattana, P, Xenaki, S, Xie, S, Xu, M, Yang, W, Yilmaz, S, Yılmaz, YF, Yotsov, T, Zahid, MT, Zielke, A, Medas, Fabio, Dobrinja, Chiara, Al-Suhaimi, Ebtesam Abdullah, Altmeier, Julia, Anajar, Said, Arikan, Akif Enes, Azaryan, Irina, Bains, Lovenish, Basili, Giancarlo, Bolukbasi, Hakan, Bononi, Marco, Borumandi, Farzad, Bozan, Mehmet Buğra, Brenta, Gabriela, Brunaud, Laurent, Brunner, Maximilian, Buemi, Antoine, Canu, Gian Luigi, Cappellacci, Federico, Cartwright, Sara Burchfield, Castells Fusté, Ignasi, Cavalheiro, Beatriz, Cavallaro, Giuseppe, Chala, Andres, Chan, Shun Yan Bryant, Chaplin, John, Cheema, Mustafa Sajjad, Chiapponi, Costanza, Chiofalo, Maria Grazia, Chrysos, Emmanuel, D'Amore, Annamaria, de Cillia, Michael, De Crea, Carmela, de Manzini, Nicolò, de Matos, Leandro Luongo, De Pasquale, Loredana, Del Rio, Paolo, Demarchi, Marco Stefano, Dhiwakar, Muthuswamy, Donatini, Gianluca, Dora, Jose Miguel, D'Orazi, Valerio, Doulatram Gamgaram, Viyey Kishore, Eismontas, Vitalijus, Kabiri, El Hassane, El Malki, Hadj Omar, Elzahaby, Islam, Enciu, Octavian, Eskander, Antoine, Feroci, Francesco, Figueroa-Bohorquez, David, Filis, Dimitrios, Gorostidi, François, Frías-Fernández, Pedro, Gamboa-Dominguez, Armando, Genc, Volkan, Giordano, Davide, Gómez-Pedraza, Antonio, Graceffa, Giuseppa, Griffin, James, Guerreiro, Sofia Cuco, Gupta, Karan, Gupta, Keshav Kumar, Gurrado, Angela, Hajiioannou, Jiannis, Hakala, Tommi, Harahap, Wirsma Arif, Hargitai, Lindsay, Hartl, Dana, Hellmann, Andrzej, Hlozek, Jiri, Hoang, Van Trung, Iacobone, Maurizio, Innaro, Nadia, Ioannidis, Orestis, Jang, J H Isabelle, Xavier-Junior, Jose Candido, Jovanovic, Milan, Kaderli, Reto Martin, Kakamad, Fahmi, Kaliszewski, Krzysztof, Karamanliev, Martin, Katoh, Hiroshi, Košec, Andro, Kovacevic, Bozidar, Kowalski, Luiz Paulo, Králik, Robert, Yadav, Sanjay Kumar, Kumorová, Adriána, Lampridis, Savvas, Lasithiotakis, Konstantinos, Leclere, Jean-Christophe, Leong, Eugene Kwong Fei, Leow, Melvin Khee-Shing, Lim, James Y, Lino-Silva, Leonardo S, Liu, Shirley Yuk Wah, Llorach, Núria Perucho, Lombardi, Celestino Pio, López-Gómez, Javier, Lori, Eleonora, Quintanilla-Dieck, Lourdes, Lucchini, Roberta, Madani, Amin, Manatakis, Dimitrios, Markovic, Ivan, Materazzi, Gabriele, Mazeh, Haggi, Mercante, Giuseppe, Meyer-Rochow, Goswin Yason, Mihaljevic, Olgica, Miller, Julie A, Minuto, Michele, Monacelli, Massimo, Mulita, Francesk, Mullineris, Barbara, Muñoz-de-Nova, José Luis, Muradás Girardi, Fábio, Nader, Saki, Napadon, Tangjaturonrasme, Nastos, Constantinos, Offi, Chiara, Ronen, Ohad, Oragano, Luigi, Orois, Aida, Pan, Yongqin, Panagiotidis, Emmanouil, Panchangam, Ramakanth Bhargav, Papavramidis, Theodosios, Parida, Pradipta Kumar, Paspala, Anna, Pérez, Òscar Vidal, Petrovic, Sabrina, Raffaelli, Marco, Ramacciotti, Constanza Fernanda, Ratia Gimenez, Tomas, Rivo Vázquez, Ángel, Roh, Jong-Lyel, Rossi, Leonardo, Sanabria, Alvaro, Santeerapharp, Alena, Semenov, Arseny, Seneviratne, Sanjeewa, Serdar, Altinay, Sheahan, Patrick, Sheppard, Sean C, Slotcavage, Rachel L, Smaxwil, Constantin, Kim, Soo Young, Sorrenti, Salvatore, Spartalis, Eleftherios, Sriphrapradang, Chutintorn, Testini, Mario, Turk, Yigit, Tzikos, George, Vabalayte, Kristina, Vargas-Osorio, Kelly, Vázquez Rentería, Rafael Sebastián, Velázquez-Fernández, David, Vithana, Sanura Malinda Pallegoda, Yücel, Levent, Yulian, Erwin Danil, Zahradnikova, Petra, Zarogoulidis, Paul, Ziablitskaia, Evgeniia, Zolotoukho, Anna, and Calò, Pietro Giorgio

Published
2023
Full Text
View/download PDF

12. Novel prognostic nomogram for predicting recurrence‐free survival in medullary thyroid carcinoma

Author

Aksoy, Yagiz A, primary, Xu, Bin, additional, Viswanathan, Kartik, additional, Ahadi, Mahsa S, additional, Al Ghuzlan, Abir, additional, Alzumaili, Bayan, additional, Bani, Mohamed‐Amine, additional, Barletta, Justine A, additional, Chau, Nicole, additional, Chou, Angela, additional, Clarkson, Adele, additional, Clifton‐Bligh, Roderick J, additional, De Leo, Antonio, additional, Dogan, Snjezana, additional, Ganly, Ian, additional, Ghossein, Ronald, additional, Gild, Matti L, additional, Glover, Anthony R, additional, Hadoux, Julien, additional, Lamartina, Livia, additional, Lubin, Daniel J, additional, Magliocca, Kelly, additional, Najdawi, Fedaa, additional, Nigam, Arad, additional, Papachristos, Alex, additional, Repaci, Andrea, additional, Robinson, Bruce G, additional, Sheen, Amy, additional, Shi, Qiuying, additional, Sidhu, Stan B, additional, Sioson, Loretta, additional, Solaroli, Erica, additional, Sywak, Mark S, additional, Tallini, Giovanni, additional, Tsang, Venessa, additional, Turchini, John, additional, Untch, Brian R, additional, Gill, Anthony J, additional, and Fuchs, Talia L, additional

Published
2024
Full Text
View/download PDF

13. Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: A Paradigm Shift to Reduce Overtreatment of Indolent Tumors

Author

Nikiforov, Yuri E, Seethala, Raja R, Tallini, Giovanni, Baloch, Zubair W, Basolo, Fulvio, Thompson, Lester DR, Barletta, Justine A, Wenig, Bruce M, Al Ghuzlan, Abir, Kakudo, Kennichi, Giordano, Thomas J, Alves, Venancio A, Khanafshar, Elham, L., Sylvia, El-Naggar, Adel K, Gooding, William E, Hodak, Steven P, Lloyd, Ricardo V, Maytal, Guy, Mete, Ozgur, Nikiforova, Marina N, Nosé, Vania, Papotti, Mauro, Poller, David N, Sadow, Peter M, Tischler, Arthur S, Tuttle, R Michael, Wall, Kathryn B, LiVolsi, Virginia A, Randolph, Gregory W, and Ghossein, Ronald A

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Patient Safety, Cancer, Clinical Research, Adenocarcinoma, Follicular, Adult, Aged, Aged, 80 and over, Carcinoma, Carcinoma, Papillary, Female, Humans, Male, Medical Overuse, Middle Aged, Neoplasm Invasiveness, Retrospective Studies, Terminology as Topic, Thyroid Cancer, Papillary, Thyroid Neoplasms, Thyroid Nodule, Young Adult, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceAlthough growing evidence points to highly indolent behavior of encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC), most patients with EFVPTC are treated as having conventional thyroid cancer.ObjectiveTo evaluate clinical outcomes, refine diagnostic criteria, and develop a nomenclature that appropriately reflects the biological and clinical characteristics of EFVPTC.Design, setting, and participantsInternational, multidisciplinary, retrospective study of patients with thyroid nodules diagnosed as EFVPTC, including 109 patients with noninvasive EFVPTC observed for 10 to 26 years and 101 patients with invasive EFVPTC observed for 1 to 18 years. Review of digitized histologic slides collected at 13 sites in 5 countries by 24 thyroid pathologists from 7 countries. A series of teleconferences and a face-to-face conference were used to establish consensus diagnostic criteria and develop new nomenclature.Main outcomes and measuresFrequency of adverse outcomes, including death from disease, distant or locoregional metastases, and structural or biochemical recurrence, in patients with noninvasive and invasive EFVPTC diagnosed on the basis of a set of reproducible histopathologic criteria.ResultsConsensus diagnostic criteria for EFVPTC were developed by 24 thyroid pathologists. All of the 109 patients with noninvasive EFVPTC (67 treated with only lobectomy, none received radioactive iodine ablation) were alive with no evidence of disease at final follow-up (median [range], 13 [10-26] years). An adverse event was seen in 12 of 101 (12%) of the cases of invasive EFVPTC, including 5 patients developing distant metastases, 2 of whom died of disease. Based on the outcome information for noninvasive EFVPTC, the name "noninvasive follicular thyroid neoplasm with papillary-like nuclear features" (NIFTP) was adopted. A simplified diagnostic nuclear scoring scheme was developed and validated, yielding a sensitivity of 98.6% (95% CI, 96.3%-99.4%), specificity of 90.1% (95% CI, 86.0%-93.1%), and overall classification accuracy of 94.3% (95% CI, 92.1%-96.0%) for NIFTP.Conclusions and relevanceThyroid tumors currently diagnosed as noninvasive EFVPTC have a very low risk of adverse outcome and should be termed NIFTP. This reclassification will affect a large population of patients worldwide and result in a significant reduction in psychological and clinical consequences associated with the diagnosis of cancer.

Published
2016

15. Alkylating Agent-Induced High Tumor Mutational Burden in Medullary Thyroid Cancer and Response to Immune Checkpoint Inhibitors: Two Case Reports

Author

Moog, Sophie, primary, Lamartina, Livia, additional, Bani, Mohamed-Amine, additional, Al Ghuzlan, Abir, additional, Friboulet, Luc, additional, Italiano, Antoine, additional, Lacroix, Ludovic, additional, Postel Vinay, Sophie, additional, Tselikas, Lambros, additional, Deschamps, Frédéric, additional, Bonnet, Baptiste, additional, Pani, Fabiana, additional, Baudin, Eric, additional, and Hadoux, Julien, additional

Published
2023
Full Text
View/download PDF

16. Association of the Genomic Profile of Medullary Thyroid Carcinoma with Tumor Characteristics and Clinical Outcomes in an International Multicenter Study

Author

Xu, Bin, primary, Viswanathan, Kartik, additional, Ahadi, Mahsa S., additional, Ahmadi, Sara, additional, Alzumaili, Bayan, additional, Bani, Mohamed-Amine, additional, Baudin, Eric, additional, Behrman, David Blake, additional, Capelletti, Marzia, additional, Chau, Nicole G, additional, Chiarucci, Federico, additional, Chou, Angela, additional, Clifton-Bligh, Roderick, additional, Coluccelli, Sara, additional, de Biase, Dario, additional, De Leo, Antonio, additional, Dogan, Snjezana, additional, Fagin, James A, additional, Fuchs, Talia, additional, Glover, Anthony Robert, additional, Hadoux, Julien, additional, Lacroix, Ludovic, additional, Lamartina, Livia, additional, Lubin, Daniel J., additional, Luxford, Catherine, additional, Magliocca, Kelly, additional, Maloberti, Thais, additional, Mohanty, Abhinita S., additional, Najdawi, Fedaa, additional, Nigam, Aradhya, additional, Papachristos, Alexander James, additional, Repaci, Andrea, additional, Robinson, Bruce, additional, Scoazec, Jean-Yves, additional, Shi, Qiuying, additional, Sidhu, Stan, additional, Solaroli, Erica, additional, Sywak, Mark, additional, Tuttle, R Michael, additional, Untch, Brian R, additional, Barletta, Justine A, additional, Al Ghuzlan, Abir, additional, Gill, Anthony J, additional, Ghossein, Ronald, additional, Tallini, Giovanni, additional, and Ganly, Ian, additional

Published
2023
Full Text
View/download PDF

17. Estimabl2 trial: Thyroidectomy without radioiodine in patients with low-risk thyroid cancer, 5 years of follow-up

Author

Lamartina, L., primary, Leboulleux, S., additional, Bournaud, C., additional, Chougnet, C., additional, Zerdoud, S., additional, Do Cao, C., additional, Catargi, B., additional, Dygai, I., additional, Kelly, A., additional, Barge, M.L., additional, Vera, P., additional, Rusu, D., additional, Schneegans, O., additional, Roux, J., additional, Klein, M., additional, Benisvy, D., additional, Eberle, M.C., additional, Bidault, S., additional, Nascimento, C., additional, Bastie, D., additional, Giraudet, A.L., additional, Bardet, S., additional, Le Moullec, N., additional, Roudaut, N., additional, Drui, D., additional, Godbert, Y., additional, Zalzali, M., additional, Drutel, A., additional, Morel, O., additional, Velayoudom, F.L., additional, Al Ghuzlan, A., additional, Schlumberger, M., additional, Buffet, C., additional, and Borget, I., additional

Published
2023
Full Text
View/download PDF

18. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Sophie Leboulleux, Christine Do Cao, Slimane Zerdoud, Marie Attard, Claire Bournaud, Ludovic Lacroix, Danielle Benisvy, David Taïeb, Stéphane Bardet, Marie Terroir-Cassou-Mounat, Nadège Anizan, Emilie Bouvier-Morel, Livia Lamartina, Georges Lion, Sarah Betrian, Christophe Sajous, Aurélie Schiazza, Marie-Eve Garcia, Renaud Ciappuccini, Martin Schlumberger, Abir Al Ghuzlan, Yann Godbert, and Isabelle Borget

Subjects
Cancer Research, Oncology
Abstract

Purpose: To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.V600E mutation. Patients and Methods: A prospective phase II trial including patients with RECIST progression within 18 months and no lesion > 3 cm. Following a baseline recombinant human (rh)TSH-stimulated diagnostic whole-body scan (dc1-WBS), dabrafenib and trametinib were given for 42 days. A second rhTSH-stimulated dc WBS (dc2-WBS) was done at day 28 and 131I (5.5 GBq–150 mCi after rhTSH) was administered at day 35. Primary endpoint was the 6-month RECIST objective response rate. In case of partial response (PR) at 6 or 12 months, a second treatment course could be given. Among 24 enrolled patients, 21 were evaluable at 6 months. Results: Abnormal 131I uptake was present on 5%, 65%, and 95% of the dc1-WBS, dc2-WBS, and post-therapy scans, respectively. At 6 months, PR was achieved in 38%, stable disease in 52%, and progressive disease (PD) in 10%. Ten patients received a second treatment course: one complete response and 6 PRs were observed at 6 months. The median progression-free survival (PFS) was not reached. The 12- and 24-month PFS were 82% and 68%, respectively. One death due to PD occurred at 24 months. Adverse events (AE) occurred in 96% of the patients, with 10 grade 3–4 AEs in 7 patients. Conclusions: Dabrafenib-trametinib is effective in BRAF p.V600E-mutated DTC patients for restoring 131I uptake with PR observed 6 months after 131I administration in 38% of the patients.

Published
2023
Full Text
View/download PDF

19. Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation

Author

Renaudin, Karine, Smati, Sarra, Wargny, Matthieu, Al Ghuzlan, Abir, Aubert, Sébastien, Leteurtre, Emmanuelle, Patey, Martine, Sibony, Mathilde, Sturm, Nathalie, Tissier, Frédérique, Amar, Laurence, Bertherat, Jérôme, Berthozat, Claudine, Chabre, Olivier, Do Cao, Christine, Haissaguerre, Magalie, Pierre, Peggy, Briet, Claire, Vezzosi, Delphine, Lifante, Jean Christophe, Pattou, François, Mirallie, Eric, Baudin, Eric, Cariou, Bertrand, Libe, Rossella, and Drui, Delphine

Published
2018
Full Text
View/download PDF

20. Ki67 proliferation index in medullary thyroid carcinoma: a comparative study of multiple counting methods and validation of image analysis and deep learning platforms

Author

Nadeem, Saad, primary, Hanna, Matthew G, additional, Viswanathan, Kartik, additional, Marino, Joseph, additional, Ahadi, Mahsa, additional, Alzumaili, Bayan, additional, Bani, Mohamed‐Amine, additional, Chiarucci, Federico, additional, Chou, Angela, additional, De Leo, Antonio, additional, Fuchs, Talia L, additional, Lubin, Daniel J, additional, Luxford, Catherine, additional, Magliocca, Kelly, additional, Martinez, Germán, additional, Shi, Qiuying, additional, Sidhu, Stan, additional, Al Ghuzlan, Abir, additional, Gill, Anthony J, additional, Tallini, Giovanni, additional, Ghossein, Ronald, additional, and Xu, Bin, additional

Published
2023
Full Text
View/download PDF

21. Factors associated with survival in anaplastic thyroid carcinoma: A multi-center study from the ENDOCAN-TUTHYREF network

Author

JANNIN, Arnaud, primary, Giudici, Fabiola, additional, de la Fouchardiere, Christelle, additional, Al Ghuzlan, Abir, additional, Wassermann, Johanna, additional, Chougnet, Cecile N, additional, Drui, Delphine, additional, Godbert, Yann, additional, Illouz, Frédéric, additional, Bardet, Stéphane, additional, Zanetta, Sylvie, additional, Roudaut, Nathalie, additional, Batisse-Lignier, Marie, additional, Groussin, Lionel, additional, klein, marc olivier, additional, Zerdoud, Slimane, additional, Lamartina, Livia, additional, Baudin, Eric, additional, Decaussin-Petrucci, Myriam, additional, Leteurtre, Emmanuelle, additional, Borson-Chazot, Francoise, additional, Do Cao, Christine, additional, Borget, Isabelle, additional, and Hadoux, Julien, additional

Published
2023
Full Text
View/download PDF

24. Radioactive iodine therapy, molecular imaging and serum biomarkers for differentiated thyroid cancer: 2017 guidelines of the French Societies of Nuclear Medicine, Endocrinology, Pathology, Biology, Endocrine Surgery and Head and Neck Surgery

Author

Zerdoud, Slimane, Giraudet, Anne-Laure, Leboulleux, Sophie, Leenhardt, Laurence, Bardet, Stéphane, Clerc, Jérôme, Toubert, Marie-Elisabeth, Al Ghuzlan, Abir, Lamy, Pierre-Jean, Bournaud, Claire, Keller, Isabelle, Sebag, Frédéric, Garrel, Renaud, Mirallié, Eric, Groussin, Lionel, Hindié, Elif, and Taïeb, David

Published
2017
Full Text
View/download PDF

25. Intraoperative Parathyroid Gland Identification Using Autofluorescence Imaging in Thyroid Cancer Surgery with Central Neck Dissection: Impact on Post-Operative Hypocalcemia.

Author

Guerlain, Joanne, Breuskin, Ingrid, Abbaci, Muriel, Lamartina, Livia, Hadoux, Julien, Baudin, Eric, Al Ghuzlan, Abir, Moog, Sophie, Marhic, Alix, Villard, Adrien, Obongo, Rais, and Hartl, Dana M.

Subjects
SURGICAL therapeutics, NECK surgery, THYROIDECTOMY, THYROID gland tumors, SURGICAL complications, RETROSPECTIVE studies, DIAGNOSTIC imaging, HYPOPARATHYROIDISM, CANCER patients, HYPOCALCEMIA, PARATHYROID glands, LONGITUDINAL method
Abstract

Simple Summary: This study describes the impact of near-infrared autofluorescence (NIRAF) on identifying the parathyroid glands on post-operative hypocalcemia in cancer surgery with total thyroidectomy, systematically associated with central neck dissection. In our study, the use of NIRAF significantly decreased the rate of PO hypocalcemia <2.10 mmol/L (36% vs. 60%, p = 0.003). Our study highlights the fact that NIRAF is a surgically non-invasive adjunct, and can improve patients' outcomes for thyroid cancer surgery by reducing post-operative temporary hypoparathyroidism for patients, with excellent oncologic prognosis. Hypoparathyroidism is the most frequent complication in thyroid surgery. The aim of this study was to evaluate the impact of intraoperative parathyroid gland identification, using autofluorescence imaging, on the rate of post-operative (PO) hypoparathyroidism in thyroid cancer surgery. Patients undergoing total thyroidectomy with central neck dissection from 2018 to 2022 were included. A prospective cohort of 77 patients operated on using near-infrared autofluorescence (NIRAF+) with the Fluobeam® (Fluoptics, Grenoble, France) system was compared to a retrospective cohort of 94 patients (NIR−). The main outcomes were the rate of PO hypocalcemia, with three cutoffs: corrected calcium (Cac) < 2.10 mmol/L, <2.00 mmol/L and <1.875 mmol/L, and the rate of permanent hypoparathyroidism, at 12 months. The rate of PO Cac < 2.10 mmol/L was statistically lower in the NIRAF+ group, compared to the control group (36% and 60%, p = 0.003, respectively). No statistically significant difference was observed for the other two thresholds. There was a lower rate of permanent hypoparathyroidism in the NIRAF+ group (5% vs. 14% in the control group), although not statistically significant (p = 0.07). NIRAF is a surgically non-invasive adjunct, and can improve patients' outcomes for thyroid cancer surgery by reducing post-operative temporary hypoparathyroidism. Larger prospective studies are warranted to validate our findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. Radiation exposure and thyroid cancer: a review

Author

Maria Laura Iglesias, Angelica Schmidt, Abir Al Ghuzlan, Ludovic Lacroix, Florent de Vathaire, Sylvie Chevillard, and Martin Schlumberger

Subjects
Differentiated thyroid carcinoma, radiation-induced thyroid cancer, radiation exposure, chernobyl accident, Medicine, Diseases of the endocrine glands. Clinical endocrinology, RC648-665
Abstract

ABSTRACT The association between radiation exposure and the occurrence of thyroid cancer has been well documented, and the two main risk factors for the development of a thyroid cancer are the radiation dose delivered to the thyroid gland and the age at exposure. The risk increases after exposure to a mean dose of more than 0.05-0.1 Gy (50-100mGy). The risk is more important during childhood and decreases with increased age at exposure, being low in adults. After exposure, the minimum latency period before the appearance of thyroid cancers is 5 to 10 years. Papillary carcinoma (PTC) is the most frequent form of thyroid carcinoma diagnosed after radiation exposure, with a higher prevalence of the solid subtype in young children with a short latency period and of the classical subtype in cases with a longer latency period after exposure. Molecular alterations, including intra-chromosomal rearrangements, are frequently found. Among them, RET/PTC rearrangements are the most frequent. Current research is directed on the mechanism of genetic alterations induced by radiation and on a molecular signature that can identify the origin of thyroid carcinoma after a known or suspected exposure to radiation.

Published
2017
Full Text
View/download PDF

28. Succinate: A Serum Biomarker of SDHB-Mutated Paragangliomas and Pheochromocytomas

Author

Constance Lamy, Hubert Tissot, Matthieu Faron, Eric Baudin, Livia Lamartina, Caroline Pradon, Abir Al Ghuzlan, Sophie Leboulleux, Jean-Luc Perfettini, Angelo Paci, Julien Hadoux, and Sophie Broutin

Subjects
Endocrinology, Diabetes and Metabolism, Biochemistry (medical), Clinical Biochemistry, Adrenal Gland Neoplasms, Succinic Acid, Pilot Projects, Pheochromocytoma, Biochemistry, Paraganglioma, Succinate Dehydrogenase, Endocrinology, Mutation, Biomarkers, Tumor, Humans, Germ-Line Mutation, Retrospective Studies
Abstract

Context Pheochromocytomas and paragangliomas (PPGL) are rare neuroendocrine tumors that are frequently associated with succinate dehydrogenase (SDH) germline mutations. When mutated, SDH losses its function, thus leading to succinate accumulation. Objective In this study, we evaluated serum succinate levels as a new metabolic biomarker in SDHx-related carriers. Methods Retrospective monocentric study of 88 PPGL patients (43 sporadic, 35 SDHB, 10 SDHA/C/D), 17 tumor-free familial asymptomatic carriers (13 SDHB, 4 SDHC/D), and 60 healthy controls. Clinical, biological, and imaging data were reviewed. Serum succinate levels (n = 280) were quantified by an ultra-performance liquid chromatography coupled to a tandem mass spectrometry method and correlated to SDHx mutational status, disease extension, and other biological biomarkers. Results Serum succinate levels > 7 μM allowed identification of tumor-free asymptomatic SDHB-mutated cases compared to a healthy control group (100% specificity; 85% sensitivity). At PPGL diagnosis, SDHB-mutated patients had a significantly increased median succinate level (14 μM) compared to sporadic patients (8 μM) (P Conclusions In this pilot study, we showed that serum succinate level is an oncometabolic biomarker that should be useful to identify SDHB-related carriers. Succinate levels are also a marker of metabolic tumor burden in patients with a metastatic PPGL and a potential marker of treatment response and follow-up.

Published
2022
Full Text
View/download PDF

29. New endpoints in adrenocortical carcinoma studies: a mini review

Author

Matthieu Faron, Livia Lamartina, Segolene Hescot, Sophie Moog, Frederic Deschamps, Charles Roux, Rosella Libe, Jerome Durand-Labrunie, Abir Al Ghuzlan, Julien Hadoux, and Eric Baudin

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Adrenocortical Carcinoma, Quality of Life, Humans, Adrenal Cortex Neoplasms, Disease-Free Survival
Abstract

Adrenocortical carcinoma (ACC) is a very rare and aggressive malignant disease. Therefore, overall survival (OS) has long been considered as the best endpoint. Yet, a unique endpoint is not optimal to take into account the heterogeneity in tumor profile and the diversification of therapeutic option. The purpose of this mini review was to describe endpoints used in the past, present and future in the field of ACC.Pubmed and Clinicaltrial.gov were used to identify relevant studies.Before year 2000 only three endpoints were regularly used: OS, recurrence-free survival (RFS) and response rate. These endpoints were used because ACC was seen as a homogeneous diseases with a high recurrence rate and low rate of long-term survival. Since 2000; along with the apparition of new class of drug, progression-free survival (PFS) has been more and more used. Other endpoints as "time to chemotherapy" or "Progression-free survival 2" were used to evaluate multimodal therapies or treatment with a delayed action. Finally, there is a hope that in the near future, quality of life along with other patient-reported outcomes may be used more frequently.While OS and PFS are currently the most used endpoints in ACC, new endpoints are needed to better take into account the challenges offered by different situations and treatment strategies.

Published
2022
Full Text
View/download PDF

30. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

Author

Medas, Fabio, primary, Dobrinja, Chiara, additional, Al-Suhaimi, Ebtesam Abdullah, additional, Altmeier, Julia, additional, Anajar, Said, additional, Arikan, Akif Enes, additional, Azaryan, Irina, additional, Bains, Lovenish, additional, Basili, Giancarlo, additional, Bolukbasi, Hakan, additional, Bononi, Marco, additional, Borumandi, Farzad, additional, Bozan, Mehmet Buğra, additional, Brenta, Gabriela, additional, Brunaud, Laurent, additional, Brunner, Maximilian, additional, Buemi, Antoine, additional, Canu, Gian Luigi, additional, Cappellacci, Federico, additional, Cartwright, Sara Burchfield, additional, Castells Fusté, Ignasi, additional, Cavalheiro, Beatriz, additional, Cavallaro, Giuseppe, additional, Chala, Andres, additional, Chan, Shun Yan Bryant, additional, Chaplin, John, additional, Cheema, Mustafa Sajjad, additional, Chiapponi, Costanza, additional, Chiofalo, Maria Grazia, additional, Chrysos, Emmanuel, additional, D'Amore, Annamaria, additional, de Cillia, Michael, additional, De Crea, Carmela, additional, de Manzini, Nicolò, additional, de Matos, Leandro Luongo, additional, De Pasquale, Loredana, additional, Del Rio, Paolo, additional, Demarchi, Marco Stefano, additional, Dhiwakar, Muthuswamy, additional, Donatini, Gianluca, additional, Dora, Jose Miguel, additional, D'Orazi, Valerio, additional, Doulatram Gamgaram, Viyey Kishore, additional, Eismontas, Vitalijus, additional, Kabiri, El Hassane, additional, El Malki, Hadj Omar, additional, Elzahaby, Islam, additional, Enciu, Octavian, additional, Eskander, Antoine, additional, Feroci, Francesco, additional, Figueroa-Bohorquez, David, additional, Filis, Dimitrios, additional, Gorostidi, François, additional, Frías-Fernández, Pedro, additional, Gamboa-Dominguez, Armando, additional, Genc, Volkan, additional, Giordano, Davide, additional, Gómez-Pedraza, Antonio, additional, Graceffa, Giuseppa, additional, Griffin, James, additional, Guerreiro, Sofia Cuco, additional, Gupta, Karan, additional, Gupta, Keshav Kumar, additional, Gurrado, Angela, additional, Hajiioannou, Jiannis, additional, Hakala, Tommi, additional, Harahap, Wirsma Arif, additional, Hargitai, Lindsay, additional, Hartl, Dana, additional, Hellmann, Andrzej, additional, Hlozek, Jiri, additional, Hoang, Van Trung, additional, Iacobone, Maurizio, additional, Innaro, Nadia, additional, Ioannidis, Orestis, additional, Jang, J H Isabelle, additional, Xavier-Junior, Jose Candido, additional, Jovanovic, Milan, additional, Kaderli, Reto Martin, additional, Kakamad, Fahmi, additional, Kaliszewski, Krzysztof, additional, Karamanliev, Martin, additional, Katoh, Hiroshi, additional, Košec, Andro, additional, Kovacevic, Bozidar, additional, Kowalski, Luiz Paulo, additional, Králik, Robert, additional, Yadav, Sanjay Kumar, additional, Kumorová, Adriána, additional, Lampridis, Savvas, additional, Lasithiotakis, Konstantinos, additional, Leclere, Jean-Christophe, additional, Leong, Eugene Kwong Fei, additional, Leow, Melvin Khee-Shing, additional, Lim, James Y, additional, Lino-Silva, Leonardo S, additional, Liu, Shirley Yuk Wah, additional, Llorach, Núria Perucho, additional, Lombardi, Celestino Pio, additional, López-Gómez, Javier, additional, Lori, Eleonora, additional, Quintanilla-Dieck, Lourdes, additional, Lucchini, Roberta, additional, Madani, Amin, additional, Manatakis, Dimitrios, additional, Markovic, Ivan, additional, Materazzi, Gabriele, additional, Mazeh, Haggi, additional, Mercante, Giuseppe, additional, Meyer-Rochow, Goswin Yason, additional, Mihaljevic, Olgica, additional, Miller, Julie A, additional, Minuto, Michele, additional, Monacelli, Massimo, additional, Mulita, Francesk, additional, Mullineris, Barbara, additional, Muñoz-de-Nova, José Luis, additional, Muradás Girardi, Fábio, additional, Nader, Saki, additional, Napadon, Tangjaturonrasme, additional, Nastos, Constantinos, additional, Offi, Chiara, additional, Ronen, Ohad, additional, Oragano, Luigi, additional, Orois, Aida, additional, Pan, Yongqin, additional, Panagiotidis, Emmanouil, additional, Panchangam, Ramakanth Bhargav, additional, Papavramidis, Theodosios, additional, Parida, Pradipta Kumar, additional, Paspala, Anna, additional, Pérez, Òscar Vidal, additional, Petrovic, Sabrina, additional, Raffaelli, Marco, additional, Ramacciotti, Constanza Fernanda, additional, Ratia Gimenez, Tomas, additional, Rivo Vázquez, Ángel, additional, Roh, Jong-Lyel, additional, Rossi, Leonardo, additional, Sanabria, Alvaro, additional, Santeerapharp, Alena, additional, Semenov, Arseny, additional, Seneviratne, Sanjeewa, additional, Serdar, Altinay, additional, Sheahan, Patrick, additional, Sheppard, Sean C, additional, Slotcavage, Rachel L, additional, Smaxwil, Constantin, additional, Kim, Soo Young, additional, Sorrenti, Salvatore, additional, Spartalis, Eleftherios, additional, Sriphrapradang, Chutintorn, additional, Testini, Mario, additional, Turk, Yigit, additional, Tzikos, George, additional, Vabalayte, Kristina, additional, Vargas-Osorio, Kelly, additional, Vázquez Rentería, Rafael Sebastián, additional, Velázquez-Fernández, David, additional, Vithana, Sanura Malinda Pallegoda, additional, Yücel, Levent, additional, Yulian, Erwin Danil, additional, Zahradnikova, Petra, additional, Zarogoulidis, Paul, additional, Ziablitskaia, Evgeniia, additional, Zolotoukho, Anna, additional, Calò, Pietro Giorgio, additional, Abdallah, A, additional, Abentroth, AL, additional, Acheimastos, V, additional, Agunaoun, M, additional, Al Bisher, HM, additional, Al Ghuzlan, A, additional, Alakus, H, additional, Alkan, M, additional, Almaraz Almaraz, MC, additional, Amram, K, additional, Anesidis, S, additional, Anestiadou, E, additional, Angelucci, D, additional, Ansaldo, GL, additional, Antonopoulou, MI, additional, Arciniegas, M, additional, Armellin, C, additional, Arredondo Saldaña, G, additional, Astl, J, additional, Athanasakis, E, additional, Avenia, S, additional, Aydın, H, additional, Baba, B, additional, Babala, J, additional, Banús, MV, additional, Barba-Valadez, LA, additional, Barcons, SV, additional, Battafarano, F, additional, Bayat, A, additional, Bella, RMC, additional, Benariba, F, additional, Bernardi, S, additional, Bignami, EG, additional, Bitenc, M, additional, Bitsianis, S, additional, Bolaños de la Torre, JDD, additional, Bonati, E, additional, Bonetti, T, additional, Borges, FA, additional, Bouchagier, K, additional, Boudina, M, additional, Bourial, A, additional, Breuskin, I, additional, Brock, P, additional, Bruns, C, additional, Burlacu, MC, additional, Burton, T, additional, Buta, M, additional, Buzanakov, D, additional, Caliseo, C, additional, Callanan, D, additional, Calu, V, additional, Cameselle-Teijeiro, JM, additional, Camilo-Junior, DJ, additional, Canberk, S, additional, Candalise, V, additional, Candanedo-Gonzalez, F, additional, Carrillo Lizarazo, LJ, additional, Carvalho, GB, additional, Casallas, D, additional, Casolino, C, additional, Castellani, L, additional, Castillo Morales, C, additional, Chambon, G, additional, Chatzipavlidou, V, additional, Chernikov, R, additional, Chorti, A, additional, Chow, TCM, additional, Chrisoulidou, A, additional, Chrysos, E, additional, Conrado-Neto, S, additional, Cordova García, D, additional, Corigliano, A, additional, Crocco, A, additional, Cuesta, A, additional, Čukman, M, additional, Curto, LS, additional, Damilano, RA, additional, D'Anna, R, additional, De, M, additional, De Virgilio, A, additional, Dellaportas, D, additional, Demarquet, L, additional, Devresse, A, additional, Di Meo, G, additional, Diaz Pedrero, R, additional, Dimitrov, D, additional, Dmitry, Z, additional, Domínguez Garijo, P, additional, Dulgeroglu, O, additional, Dural, AC, additional, Eksi, A, additional, El Hammoumi, M, additional, El Kaoui, H, additional, Eleni, G, additional, Elliyanti, A, additional, Ersöz, Ş, additional, Escobar-Jiménez, M, additional, Fedorova, L, additional, Feeley, L, additional, Fernández Rodríguez, E, additional, Ferreli, F, additional, Filoia, A, additional, Fingeret, A, additional, Francescato, A, additional, Gaino, F, additional, Galiandro, F, additional, Gallegos-Hernández, JF, additional, Garas, G, additional, García Lorenzo, F, additional, García-Chávez, JP, additional, Gaudiello, M, additional, Gay, S, additional, Gerasimos, S, additional, Gerek, M, additional, Gervasi, R, additional, Giordano, A, additional, Gjeloshi, B, additional, Gocký, L, additional, Golubinskaya, E, additional, González Romero, S, additional, González-Mínguez, C, additional, Goran, M, additional, Gosman, A, additional, Granados Garcia, M, additional, Greco, E, additional, Grünbart, M, additional, Grützmann, R, additional, Guerlain, J, additional, Guirao, XG, additional, Guzey, D, additional, Hajjij, A, additional, Hamdy, O, additional, Hameed, MS, additional, Hauth, LA, additional, Hernández-Acevedo, JD, additional, Hernandez-Carrillo, JF, additional, Hevilla Sánchez, F, additional, Hoi, H, additional, Hongkwon, K, additional, Hu Zhu, R, additional, Huang, E, additional, Hyeung Kyoo, K, additional, Ignjatovic, V, additional, Ioannidis, A, additional, Iossa, A, additional, Işık, A, additional, James, D, additional, Jung Hoon, L, additional, Kara, H, additional, Karajovic, J, additional, Kartini, D, additional, Khambri, D, additional, Kholová, I, additional, Kisiel, M, additional, Knežević, M, additional, Koh, YQ, additional, Konca, C, additional, Kosmidis, C, additional, Kotsovolis, G, additional, Kowalski, LP, additional, Kralik, R, additional, Kuczma, P, additional, Kuravi, BG, additional, Kurnia, A, additional, Kyriaki, V, additional, Lai, CM, additional, Lallemant, B, additional, Lardhi, AA, additional, Leboulleux, S, additional, Lee, JW, additional, Lelli, G, additional, Leutner, M, additional, Lim, MY, additional, Lim, CM, additional, Llanos, A, additional, Lo, X, additional, Loderer, T, additional, López-Corrales, MA, additional, Ludwig, M, additional, Magnabosco, FF, additional, Maheo, C, additional, Maia, AL, additional, Makay, O, additional, Maksimova, P, additional, Mallick, S, additional, Mallouk, C, additional, Mamani, Z, additional, Mandal, S, additional, Manyalich Blasi, M, additional, Marincola, G, additional, Marulanda, M, additional, Mavromati, M, additional, Mayilvaganan, S, additional, Metso, S, additional, Micalizzi, A, additional, Michalopoulos, A, additional, Min-Su, K, additional, Miron, A, additional, Mishra, AK, additional, Misso, C, additional, Mittermair, C, additional, Morosán Allo, Y, additional, Mourad, M, additional, Moysidis, M, additional, Nabhan, F, additional, Nasiri, R, additional, Nastos, C, additional, Ngiam, KY, additional, Nomine-Criqui, C, additional, Ntziovara, AM, additional, Nuño Vázquez-Garza, JM, additional, Nutautiene, V, additional, Obtulovičová, K, additional, O'Keeffe, L, additional, Okudur, NO, additional, Ossola, P, additional, Ovejero Merino, E, additional, Ozdemir, M, additional, Pangonis, A, additional, Panigoro, SS, additional, Panuzi, A, additional, Papaconstantinou, D, additional, Pardo Matamoros, N, additional, Paschou, S, additional, Pasculli, A, additional, Paterakis, K, additional, Peiris, K, additional, Pennestrì, F, additional, Peppa, M, additional, Perdikaris, P, additional, Perdikaris, I, additional, Pérez-Soto, RH, additional, Piana, S, additional, Piccoli, M, additional, Pietrasanta, D, additional, Placentino, G, additional, Pliakos, I, additional, Polistena, A, additional, Pongtippan, A, additional, Potard, G, additional, Quinn, V, additional, Rahul, P, additional, Ramos, T, additional, Rankin, A, additional, Ratnayake, P, additional, Reuto-Castillo, J, additional, Ridolfo, A, additional, Rios-Valencia, J, additional, Riss, P, additional, Rival, E, additional, Rivillas, J, additional, Roi, D, additional, Rollo, EM, additional, Romanchishen, A, additional, Romito, M, additional, Rotnagl, J, additional, Rovcanin, B, additional, Russo, G, additional, Sabol, M, additional, Saki, S, additional, Saleh, S, additional, Salih, A, additional, Saltiki, A, additional, Salvador-Camarmo, G, additional, Samal, DK, additional, Sánchez-Flores, S, additional, Sapalidis, K, additional, Sarin, D, additional, Sarin, H, additional, Savkovic, N, additional, Scheffel, RS, additional, Scheinpflug, AL, additional, Scheuba, C, additional, Scheyer, N, additional, Schmidt, M, additional, Senashova, O, additional, Serafini, E, additional, Serrano Arévalo, ML, additional, Shank, J, additional, Shindo, ML, additional, Shoshkova, M, additional, Shvan, M, additional, Sičák, M, additional, Silva, TG, additional, Simó Guerrero, O, additional, Skuletic, V, additional, Slijepcevic, N, additional, Slovic, Z, additional, Soares, P, additional, Somova, A, additional, Soto, S, additional, Spiezia, S, additional, Stankovic, V, additional, Stephenson, KJ, additional, Straub, E, additional, Summa, M, additional, Surani, S, additional, Syed, AA, additional, Symeonidis, S, additional, Taciak, A, additional, Tarallo, M, additional, Tarle, A, additional, Tasis, N, additional, Tausanovic, K, additional, Tchabashvili, L, additional, Thierry, M, additional, Tokarczyk, U, additional, Toma, EA, additional, Topuz, S, additional, Torresan, F, additional, Uras, C, additional, Vaccaro, C, additional, Valdés de Anca, Á, additional, Valentini, M, additional, Varaldo, E, additional, Vartanian, JG, additional, Verras, GI, additional, Vithanage, A, additional, Wijayalathge, H, additional, Wiriyaamornchai, P, additional, Wong, YLC, additional, Wongwattana, P, additional, Xenaki, S, additional, Xie, S, additional, Xu, M, additional, Yang, W, additional, Yilmaz, S, additional, Yılmaz, YF, additional, Yotsov, T, additional, Zahid, MT, additional, and Zielke, A, additional

Published
2023
Full Text
View/download PDF

31. Supplementary Table S5 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Leboulleux, Sophie, primary, Do Cao, Christine, primary, Zerdoud, Slimane, primary, Attard, Marie, primary, Bournaud, Claire, primary, Lacroix, Ludovic, primary, Benisvy, Danielle, primary, Taïeb, David, primary, Bardet, Stéphane, primary, Terroir-Cassou-Mounat, Marie, primary, Anizan, Nadège, primary, Bouvier-Morel, Emilie, primary, Lamartina, Livia, primary, Lion, Georges, primary, Betrian, Sarah, primary, Sajous, Christophe, primary, Schiazza, Aurélie, primary, Garcia, Marie-Eve, primary, Ciappuccini, Renaud, primary, Schlumberger, Martin, primary, Al Ghuzlan, Abir, primary, Godbert, Yann, primary, and Borget, Isabelle, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure S2 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Leboulleux, Sophie, primary, Do Cao, Christine, primary, Zerdoud, Slimane, primary, Attard, Marie, primary, Bournaud, Claire, primary, Lacroix, Ludovic, primary, Benisvy, Danielle, primary, Taïeb, David, primary, Bardet, Stéphane, primary, Terroir-Cassou-Mounat, Marie, primary, Anizan, Nadège, primary, Bouvier-Morel, Emilie, primary, Lamartina, Livia, primary, Lion, Georges, primary, Betrian, Sarah, primary, Sajous, Christophe, primary, Schiazza, Aurélie, primary, Garcia, Marie-Eve, primary, Ciappuccini, Renaud, primary, Schlumberger, Martin, primary, Al Ghuzlan, Abir, primary, Godbert, Yann, primary, and Borget, Isabelle, primary

Published
2023
Full Text
View/download PDF

33. Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Leboulleux, Sophie, primary, Do Cao, Christine, primary, Zerdoud, Slimane, primary, Attard, Marie, primary, Bournaud, Claire, primary, Lacroix, Ludovic, primary, Benisvy, Danielle, primary, Taïeb, David, primary, Bardet, Stéphane, primary, Terroir-Cassou-Mounat, Marie, primary, Anizan, Nadège, primary, Bouvier-Morel, Emilie, primary, Lamartina, Livia, primary, Lion, Georges, primary, Betrian, Sarah, primary, Sajous, Christophe, primary, Schiazza, Aurélie, primary, Garcia, Marie-Eve, primary, Ciappuccini, Renaud, primary, Schlumberger, Martin, primary, Al Ghuzlan, Abir, primary, Godbert, Yann, primary, and Borget, Isabelle, primary

Published
2023
Full Text
View/download PDF

34. Impact of vascular invasion on otherwise low-risk papillary thyroid carcinomas: a retrospective and observational study

Author

Marques, Puga Francisca, primary, Al, Ghuzlan Abir, additional, Hartl, Dana M., additional, Bani, Mohamed-Amine, additional, Moog, Sophie, additional, Pani, Fabiana, additional, Breuskin, Ingrid, additional, Guerlain, Joanne, additional, Faron, Matthieu, additional, Denadreis, Desiree, additional, Baudin, Eric, additional, Hadoux, Julien, additional, and Lamartina, Livia, additional

Published
2023
Full Text
View/download PDF

35. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Leboulleux, Sophie, primary, Do Cao, Christine, additional, Zerdoud, Slimane, additional, Attard, Marie, additional, Bournaud, Claire, additional, Lacroix, Ludovic, additional, Benisvy, Danielle, additional, Taïeb, David, additional, Bardet, Stéphane, additional, Terroir-Cassou-Mounat, Marie, additional, Anizan, Nadège, additional, Bouvier-Morel, Emilie, additional, Lamartina, Livia, additional, Lion, Georges, additional, Betrian, Sarah, additional, Sajous, Christophe, additional, Schiazza, Aurélie, additional, Garcia, Marie-Eve, additional, Ciappuccini, Renaud, additional, Schlumberger, Martin, additional, Al Ghuzlan, Abir, additional, Godbert, Yann, additional, and Borget, Isabelle, additional

Published
2023
Full Text
View/download PDF

36. IgG4-related sclerosing thyroiditis (Riedel-Struma): a review of clinicopathological features and management

Author

Agata Czarnywojtek, Krzysztof Pietrończyk, Lester D. R. Thompson, Asterios Triantafyllou, Ewa Florek, Nadia Sawicka-Gutaj, Marek Ruchała, Maria Teresa Płazinska, Iain J. Nixon, Ashok R. Shaha, Mark Zafereo, Gregory William Randolph, Peter Angelos, Abir Al Ghuzlan, Abbas Agaimy, and Alfio Ferlito

Subjects
Cell Biology, General Medicine, Molecular Biology, Pathology and Forensic Medicine
Abstract

We present a thorough review of the literature on Riedel thyroiditis (RT) with emphasis on aetiology, diagnosis and management, using the PubMed, Sinomed, and China National Knowledge Infrastructure databases. Although the exact aetiology of RT remains obscure, the histopathological features are consistent with a localized form of IgG4-related systemic disease (IgG4-RSD). Nevertheless, IgG4-RSD as a systemic fibroinflammatory disorder per se rarely affects the thyroid in the context of multiorgan manifestations. The initial diagnosis of RT is based on clinical history and imaging, but confirmation by histopathological examination is mandatory. In contrast to the historical surgical approach, glucocorticosteroid therapy is currently considered first line therapy, in line with the RT currently being viewed as a manifestation of, or analogous to, IgG4-RSD. For disease relapse, immunomodulatory agents (azathioprine, methotrexate, rituximab) can be used.

Published
2023
Full Text
View/download PDF

37. Supplementary Figure S1 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Isabelle Borget, Yann Godbert, Abir Al Ghuzlan, Martin Schlumberger, Renaud Ciappuccini, Marie-Eve Garcia, Aurélie Schiazza, Christophe Sajous, Sarah Betrian, Georges Lion, Livia Lamartina, Emilie Bouvier-Morel, Nadège Anizan, Marie Terroir-Cassou-Mounat, Stéphane Bardet, David Taïeb, Danielle Benisvy, Ludovic Lacroix, Claire Bournaud, Marie Attard, Slimane Zerdoud, Christine Do Cao, and Sophie Leboulleux

Abstract

Waterfall plot of the RECIST response

Published
2023
Full Text
View/download PDF

38. Supplementary Table S5 from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Isabelle Borget, Yann Godbert, Abir Al Ghuzlan, Martin Schlumberger, Renaud Ciappuccini, Marie-Eve Garcia, Aurélie Schiazza, Christophe Sajous, Sarah Betrian, Georges Lion, Livia Lamartina, Emilie Bouvier-Morel, Nadège Anizan, Marie Terroir-Cassou-Mounat, Stéphane Bardet, David Taïeb, Danielle Benisvy, Ludovic Lacroix, Claire Bournaud, Marie Attard, Slimane Zerdoud, Christine Do Cao, and Sophie Leboulleux

Abstract

Quality of Life scores

Published
2023
Full Text
View/download PDF

39. Data from A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer

Author

Isabelle Borget, Yann Godbert, Abir Al Ghuzlan, Martin Schlumberger, Renaud Ciappuccini, Marie-Eve Garcia, Aurélie Schiazza, Christophe Sajous, Sarah Betrian, Georges Lion, Livia Lamartina, Emilie Bouvier-Morel, Nadège Anizan, Marie Terroir-Cassou-Mounat, Stéphane Bardet, David Taïeb, Danielle Benisvy, Ludovic Lacroix, Claire Bournaud, Marie Attard, Slimane Zerdoud, Christine Do Cao, and Sophie Leboulleux

Abstract

Purpose:To evaluate the efficacy and safety of dabrafenib-trametinib-131I for the treatment of radioactive iodine refractory metastatic differentiated thyroid cancer (DTC) with a BRAF p.V600E mutation.Patients and Methods:A prospective phase II trial including patients with RECIST progression within 18 months and no lesion > 3 cm. Following a baseline recombinant human (rh)TSH-stimulated diagnostic whole-body scan (dc1-WBS), dabrafenib and trametinib were given for 42 days. A second rhTSH-stimulated dc WBS (dc2-WBS) was done at day 28 and 131I (5.5 GBq–150 mCi after rhTSH) was administered at day 35. Primary endpoint was the 6-month RECIST objective response rate. In case of partial response (PR) at 6 or 12 months, a second treatment course could be given. Among 24 enrolled patients, 21 were evaluable at 6 months.Results:Abnormal 131I uptake was present on 5%, 65%, and 95% of the dc1-WBS, dc2-WBS, and post-therapy scans, respectively. At 6 months, PR was achieved in 38%, stable disease in 52%, and progressive disease (PD) in 10%. Ten patients received a second treatment course: one complete response and 6 PRs were observed at 6 months. The median progression-free survival (PFS) was not reached. The 12- and 24-month PFS were 82% and 68%, respectively. One death due to PD occurred at 24 months. Adverse events (AE) occurred in 96% of the patients, with 10 grade 3–4 AEs in 7 patients.Conclusions:Dabrafenib-trametinib is effective in BRAF p.V600E-mutated DTC patients for restoring 131I uptake with PR observed 6 months after 131I administration in 38% of the patients.

Published
2023
Full Text
View/download PDF

40. Factors Associated with Survival in Anaplastic Thyroid Carcinoma: A Multicenter Study from the ENDOCAN-TUTHYREF Network.

Author

Jannin, Arnaud, Giudici, Fabiola, de la Fouchardière, Christelle, Al Ghuzlan, Abir, Wassermann, Johanna, Chougnet, Cecile N., Drui, Delphine, Godbert, Yann, Ilouz, Frédéric, Bardet, Stéphane, Zanetta, Sylvie, Roudaut, Nathalie, Batisse Lignier, Marie, Groussin, Lionel, Klein, Marc, Zerdoud, Slimane, Lamartina, Livia, Baudin, Eric, Decaussin-Petrucci, Myriam, and Leteurtre, Emmanuelle

Subjects
ANAPLASTIC thyroid cancer, THYROID cancer, RADIOTHERAPY, PROPORTIONAL hazards models, NEUTROPHIL lymphocyte ratio, COMBINED modality therapy
Abstract

Background: Anaplastic thyroid carcinoma (ATC) is a rare and frequently fatal type of thyroid cancer. The degree of heterogeneity in survival rates for ATC is incompletely studied. This study evaluated the factors associated with overall survival (OS) of patients with ATC using multicenter real-world data from a national tertiary care center network in France. Methods: In this multicenter, retrospective cohort study, all patients with ATC diagnosed between 2010 and 2020 were identified from the national database of the French ENDOCAN-TUTHYREF network. Factors associated with OS were examined in multivariable analyses using Cox proportional hazards models. Results: The study included 360 patients. Of these, 220 (61%) were female and the median age was 72 years (interquartile range: 62–80). The percentages of patients with pure and mixed (synchronously-transformed) ATC (p-ATC and st-ATC) were 62.5% and 26.7%, respectively. The median OS was 6.8 months [confidence interval, CI: 5.5–8.1]: not reached for stage IVa, 11.4 months [8.2–17.8] for IVb, and 4.6 months [3.5–5.7] for IVc. Surgery, radiation therapy to the neck, chemotherapy, and best supportive care were administered to 69 (19.2%), 214 (59.4%), 254 (70.6%), and 66 (18.3%) patients, respectively. In a multivariable analysis, including stage IVb–IVc patients, significantly higher OS was observed in patients with Eastern Cooperative Oncology Group performance-status of 0–1 (hazard ratio [HR], 0.6; [CI, 0.4–0.9], p < 0.02), stage IVb [HR, 0.5; CI, 0.4–0.8, p < 0.001], and multimodal treatment (surgery and chemoradiotherapy) [HR, 0.07; CI, 0.04–0.1, p < 0.001]. Variables associated with significantly worse OS included: p-ATC (vs. st-ATC) [HR, 1.83; CI, 1.33–2.51, p = 0.001] and a neutrophil-to-lymphocyte ratio (NLR) >5.05 [HR, 2.05, CI, 1.39–3.05, p < 0.001]. Conclusions: Factors independently associated with improved OS in ATC included: European Cooperative Oncology Group performance status, disease stage, multimodality treatment, synchronously transformed ATC, and lower NLR. Long-term OS was observed in selected patients with ATC who underwent multimodal treatment. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

42. Neck Surgery for Non-Well Differentiated Thyroid Malignancies: Variations in Strategy According to Histopathology

Author

López, Fernando, primary, Al Ghuzlan, Abir, additional, Zafereo, Mark, additional, Vander Poorten, Vincent, additional, Robbins, K. Thomas, additional, Hamoir, Marc, additional, Nixon, Iain J., additional, Tufano, Ralph P., additional, Randolph, Gregory, additional, Pace-Asciak, Pia, additional, Angelos, Peter, additional, Coca-Pelaz, Andrés, additional, Khafif, Avi, additional, Ronen, Ohad, additional, Rodrigo, Juan Pablo, additional, Sanabria, Álvaro, additional, Palme, Carsten E., additional, Mäkitie, Antti A., additional, Kowalski, Luiz P., additional, Rinaldo, Alessandra, additional, and Ferlito, Alfio, additional

Published
2023
Full Text
View/download PDF

43. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer

Author

Sophie Leboulleux, Claire Bournaud, Cecile N. Chougnet, Slimane Zerdoud, Abir Al Ghuzlan, Bogdan Catargi, Christine Do Cao, Antony Kelly, Marie-Luce Barge, Ludovic Lacroix, Inna Dygai, Pierre Vera, Daniela Rusu, Olivier Schneegans, Danielle Benisvy, Marc Klein, Julie Roux, Marie-Claude Eberle, Delphine Bastie, Camila Nascimento, Anne-Laure Giraudet, Nathalie Le Moullec, Stéphane Bardet, Delphine Drui, Nathalie Roudaut, Yann Godbert, Olivier Morel, Anne Drutel, Livia Lamartina, Claire Schvartz, Fritz-Line Velayoudom, Martin-Jean Schlumberger, Laurence Leenhardt, and Isabelle Borget

Subjects
General Medicine
Published
2022
Full Text
View/download PDF

44. NF1-Associated Inflammatory Polyp of the Colon: First Report of a Sporadic Case

Author

Christina Kanaan, Sophie Cotteret, Pierre Khneisser, Ranya Soufan, Mohamed-Amine Bani, Pascal Burtin, Isabelle Sourrouille, Michel Ducreux, Abir Al Ghuzlan, and Jean-Yves Scoazec

Subjects
congenital, hereditary, and neonatal diseases and abnormalities, Surgery, Anatomy, neoplasms, nervous system diseases, Pathology and Forensic Medicine
Abstract

“Juvenile-like (hyperplastic/inflammatory) mucosal polyp” is a term proposed for rare benign mesenchymal lesions of the gastro-intestinal tract so far reported only in patients with type 1 neurofibromatosis (NF1). We report here a first sporadic case of NF1-associated mucosal inflammatory polyp of the colon. The diagnosis was made in a 53-year old female patient with a large polypoid tumor of the cecum. The lesion was predominantly mucosal, made of fibroblast-like cells associated with inflammatory infiltrates rich in eosinophils and containing entrapped, distorted epithelial glands, responsible for the juvenile-like appearance. Whole exome sequencing showed a pathogenic variant of NF1. The patient had no evidence of NF1; no NF1 mutation was detected in normal tissues. Our observation may support the existence of juvenile-like inflammatory polyps associated with NF1 alterations, either germline or somatic. This justifies to test NF1 in difficult-to-classify gastrointestinal mesenchymal tumors.

Published
2022
Full Text
View/download PDF

46. Neck Surgery for Non-Well Differentiated Thyroid Malignancies: Variations in Strategy According to Histopathology

Author

Fernando López, Abir Al Ghuzlan, Mark Zafereo, Vincent Vander Poorten, K. Thomas Robbins, Marc Hamoir, Iain J. Nixon, Ralph P. Tufano, Gregory Randolph, Pia Pace-Asciak, Peter Angelos, Andrés Coca-Pelaz, Avi Khafif, Ohad Ronen, Juan Pablo Rodrigo, Álvaro Sanabria, Carsten E. Palme, Antti A. Mäkitie, Luiz P. Kowalski, Alessandra Rinaldo, and Alfio Ferlito

Subjects
Cancer Research, Science & Technology, treatment, non-well differentiated thyroid cancer, neck dissection, Thyroid cancer, CANCER, MANAGEMENT GUIDELINES, LYMPH-NODE DISSECTION, PROGNOSTIC-FACTORS, Oncology, ASSOCIATION GUIDELINES, PRIMARY LEIOMYOSARCOMA, NERVE SHEATH TUMORS, SINGLE INSTITUTION, GLAND REPORT, Life Sciences & Biomedicine, PRIMARY MUCOEPIDERMOID CARCINOMA
Abstract

Lymph node metastases in non-well differentiated thyroid cancer (non-WDTC) are common, both in the central compartment (levels VI and VII) and in the lateral neck (Levels II to V). Nodal metastases negatively affect prognosis and should be treated to maximize locoregional control while minimizing morbidity. In non-WDTC, the rate of nodal involvement is variable and depends on the histology of the tumor. For medullary thyroid carcinomas, poorly differentiated thyroid carcinomas, and anaplastic thyroid carcinomas, the high frequency of lymph node metastases makes central compartment dissection generally necessary. In mucoepidermoid carcinomas, malignant peripheral nerve sheath tumors, sarcomas, and malignant thyroid teratomas or thyroblastomas, central compartment dissection is less often necessary, as clinical lymphnode involvement is less common. We aim to summarize the medical literature and the opinions of several experts from different parts of the world on the current philosophy for managing the neck in less common types of thyroid cancer. ispartof: CANCERS vol:15 issue:4 ispartof: location:Switzerland status: published

Published
2023

47. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

Author

Fabio Medas, Chiara Dobrinja, Ebtesam Abdullah Al-Suhaimi, Julia Altmeier, Said Anajar, Akif Enes Arikan, Irina Azaryan, Lovenish Bains, Giancarlo Basili, Hakan Bolukbasi, Marco Bononi, Farzad Borumandi, Mehmet Buğra Bozan, Gabriela Brenta, Laurent Brunaud, Maximilian Brunner, Antoine Buemi, Gian Luigi Canu, Federico Cappellacci, Sara Burchfield Cartwright, Ignasi Castells Fusté, Beatriz Cavalheiro, Giuseppe Cavallaro, Andres Chala, Shun Yan Bryant Chan, John Chaplin, Mustafa Sajjad Cheema, Costanza Chiapponi, Maria Grazia Chiofalo, Emmanuel Chrysos, Annamaria D'Amore, Michael de Cillia, Carmela De Crea, Nicolò de Manzini, Leandro Luongo de Matos, Loredana De Pasquale, Paolo Del Rio, Marco Stefano Demarchi, Muthuswamy Dhiwakar, Gianluca Donatini, Jose Miguel Dora, Valerio D'Orazi, Viyey Kishore Doulatram Gamgaram, Vitalijus Eismontas, El Hassane Kabiri, Hadj Omar El Malki, Islam Elzahaby, Octavian Enciu, Antoine Eskander, Francesco Feroci, David Figueroa-Bohorquez, Dimitrios Filis, Gorostidi François, Pedro Frías-Fernández, Armando Gamboa-Dominguez, Volkan Genc, Davide Giordano, Antonio Gómez-Pedraza, Giuseppa Graceffa, James Griffin, Sofia Cuco Guerreiro, Karan Gupta, Keshav Kumar Gupta, Angela Gurrado, Jiannis Hajiioannou, Tommi Hakala, Wirsma Arif Harahap, Lindsay Hargitai, Dana Hartl, Andrzej Hellmann, Jiri Hlozek, Van Trung Hoang, Maurizio Iacobone, Nadia Innaro, Orestis Ioannidis, J H Isabelle Jang, Jose Candido Xavier-Junior, Milan Jovanovic, Reto Martin Kaderli, Fahmi Kakamad, Krzysztof Kaliszewski, Martin Karamanliev, Hiroshi Katoh, Andro Košec, Bozidar Kovacevic, Luiz Paulo Kowalski, Robert Králik, Sanjay Kumar Yadav, Adriána Kumorová, Savvas Lampridis, Konstantinos Lasithiotakis, Jean-Christophe Leclere, Eugene Kwong Fei Leong, Melvin Khee-Shing Leow, James Y Lim, Leonardo S Lino-Silva, Shirley Yuk Wah Liu, Núria Perucho Llorach, Celestino Pio Lombardi, Javier López-Gómez, Eleonora Lori, Lourdes Quintanilla-Dieck, Roberta Lucchini, Amin Madani, Dimitrios Manatakis, Ivan Markovic, Gabriele Materazzi, Haggi Mazeh, Giuseppe Mercante, Goswin Yason Meyer-Rochow, Olgica Mihaljevic, Julie A Miller, Michele Minuto, Massimo Monacelli, Francesk Mulita, Barbara Mullineris, José Luis Muñoz-de-Nova, Fábio Muradás Girardi, Saki Nader, Tangjaturonrasme Napadon, Constantinos Nastos, Chiara Offi, Ohad Ronen, Luigi Oragano, Aida Orois, Yongqin Pan, Emmanouil Panagiotidis, Ramakanth Bhargav Panchangam, Theodosios Papavramidis, Pradipta Kumar Parida, Anna Paspala, Òscar Vidal Pérez, Sabrina Petrovic, Marco Raffaelli, Constanza Fernanda Ramacciotti, Tomas Ratia Gimenez, Ángel Rivo Vázquez, Jong-Lyel Roh, Leonardo Rossi, Alvaro Sanabria, Alena Santeerapharp, Arseny Semenov, Sanjeewa Seneviratne, Altinay Serdar, Patrick Sheahan, Sean C Sheppard, Rachel L Slotcavage, Constantin Smaxwil, Soo Young Kim, Salvatore Sorrenti, Eleftherios Spartalis, Chutintorn Sriphrapradang, Mario Testini, Yigit Turk, George Tzikos, Kristina Vabalayte, Kelly Vargas-Osorio, Rafael Sebastián Vázquez Rentería, David Velázquez-Fernández, Sanura Malinda Pallegoda Vithana, Levent Yücel, Erwin Danil Yulian, Petra Zahradnikova, Paul Zarogoulidis, Evgeniia Ziablitskaia, Anna Zolotoukho, Pietro Giorgio Calò, A Abdallah, AL Abentroth, V Acheimastos, M Agunaoun, HM Al Bisher, A Al Ghuzlan, H Alakus, M Alkan, MC Almaraz Almaraz, K Amram, S Anesidis, E Anestiadou, D Angelucci, GL Ansaldo, MI Antonopoulou, M Arciniegas, C Armellin, G Arredondo Saldaña, J Astl, E Athanasakis, S Avenia, H Aydın, B Baba, J Babala, MV Banús, LA Barba-Valadez, SV Barcons, F Battafarano, A Bayat, RMC Bella, F Benariba, S Bernardi, EG Bignami, M Bitenc, S Bitsianis, JDD Bolaños de la Torre, E Bonati, T Bonetti, FA Borges, K Bouchagier, M Boudina, A Bourial, I Breuskin, P Brock, C Bruns, MC Burlacu, T Burton, M Buta, D Buzanakov, C Caliseo, D Callanan, V Calu, JM Cameselle-Teijeiro, DJ Camilo-Junior, S Canberk, V Candalise, F Candanedo-Gonzalez, LJ Carrillo Lizarazo, GB Carvalho, D Casallas, C Casolino, L Castellani, C Castillo Morales, G Chambon, V Chatzipavlidou, R Chernikov, A Chorti, TCM Chow, A Chrisoulidou, E Chrysos, S Conrado-Neto, D Cordova García, A Corigliano, A Crocco, A Cuesta, M Čukman, LS Curto, RA Damilano, R D'Anna, M De, A De Virgilio, D Dellaportas, L Demarquet, A Devresse, G Di Meo, R Diaz Pedrero, D Dimitrov, Z Dmitry, P Domínguez Garijo, O Dulgeroglu, AC Dural, A Eksi, M El Hammoumi, H El Kaoui, G Eleni, A Elliyanti, Ş Ersöz, M Escobar-Jiménez, L Fedorova, L Feeley, E Fernández Rodríguez, F Ferreli, A Filoia, A Fingeret, A Francescato, F Gaino, F Galiandro, JF Gallegos-Hernández, G Garas, F García Lorenzo, JP García-Chávez, M Gaudiello, S Gay, S Gerasimos, M Gerek, R Gervasi, A Giordano, B Gjeloshi, L Gocký, E Golubinskaya, S González Romero, C González-Mínguez, M Goran, A Gosman, M Granados Garcia, E Greco, M Grünbart, R Grützmann, J Guerlain, XG Guirao, D Guzey, A Hajjij, O Hamdy, MS Hameed, LA Hauth, JD Hernández-Acevedo, JF Hernandez-Carrillo, F Hevilla Sánchez, H Hoi, K Hongkwon, R Hu Zhu, E Huang, K Hyeung Kyoo, V Ignjatovic, A Ioannidis, A Iossa, A Işık, D James, L Jung Hoon, H Kara, J Karajovic, D Kartini, D Khambri, I Kholová, M Kisiel, M Knežević, YQ Koh, C Konca, C Kosmidis, G Kotsovolis, LP Kowalski, R Kralik, P Kuczma, BG Kuravi, A Kurnia, V Kyriaki, CM Lai, B Lallemant, AA Lardhi, S Leboulleux, JW Lee, G Lelli, M Leutner, MY Lim, CM Lim, A Llanos, X Lo, T Loderer, MA López-Corrales, M Ludwig, FF Magnabosco, C Maheo, AL Maia, O Makay, P Maksimova, S Mallick, C Mallouk, Z Mamani, S Mandal, M Manyalich Blasi, G Marincola, M Marulanda, M Mavromati, S Mayilvaganan, S Metso, A Micalizzi, A Michalopoulos, K Min-Su, A Miron, AK Mishra, C Misso, C Mittermair, Y Morosán Allo, M Mourad, M Moysidis, F Nabhan, R Nasiri, C Nastos, KY Ngiam, C Nomine-Criqui, AM Ntziovara, JM Nuño Vázquez-Garza, V Nutautiene, K Obtulovičová, L O'Keeffe, NO Okudur, P Ossola, E Ovejero Merino, M Ozdemir, A Pangonis, SS Panigoro, A Panuzi, D Papaconstantinou, N Pardo Matamoros, S Paschou, A Pasculli, K Paterakis, K Peiris, F Pennestrì, M Peppa, P Perdikaris, I Perdikaris, RH Pérez-Soto, S Piana, M Piccoli, D Pietrasanta, G Placentino, I Pliakos, A Polistena, A Pongtippan, G Potard, V Quinn, P Rahul, T Ramos, A Rankin, P Ratnayake, J Reuto-Castillo, A Ridolfo, J Rios-Valencia, P Riss, E Rival, J Rivillas, D Roi, EM Rollo, A Romanchishen, M Romito, J Rotnagl, B Rovcanin, G Russo, M Sabol, S Saki, S Saleh, A Salih, A Saltiki, G Salvador-Camarmo, DK Samal, S Sánchez-Flores, K Sapalidis, D Sarin, H Sarin, N Savkovic, RS Scheffel, AL Scheinpflug, C Scheuba, N Scheyer, M Schmidt, O Senashova, E Serafini, ML Serrano Arévalo, J Shank, ML Shindo, M Shoshkova, M Shvan, M Sičák, TG Silva, O Simó Guerrero, V Skuletic, N Slijepcevic, Z Slovic, P Soares, A Somova, S Soto, S Spiezia, V Stankovic, KJ Stephenson, E Straub, M Summa, S Surani, AA Syed, S Symeonidis, A Taciak, M Tarallo, A Tarle, N Tasis, K Tausanovic, L Tchabashvili, M Thierry, U Tokarczyk, EA Toma, S Topuz, F Torresan, C Uras, C Vaccaro, Á Valdés de Anca, M Valentini, E Varaldo, JG Vartanian, GI Verras, A Vithanage, H Wijayalathge, P Wiriyaamornchai, YLC Wong, P Wongwattana, S Xenaki, S Xie, M Xu, W Yang, S Yilmaz, YF Yılmaz, T Yotsov, MT Zahid, A Zielke, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, and UCL - (SLuc) Service de néphrologie

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours. In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186. Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78·6%] female patients and 4922 [21·4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1·4 [IQR 0·6-3·4]) compared with the prepandemic phase (2·0 [0·9-3·7]; p

Published
2023

50. Les stratégies de désescalade pour les cancers différenciés de la thyroïde

Author

Abir Al Ghuzlan, Livia Lamartina, Julien Hadoux, Ingrid Breuskin, Camilo Garcia, Eric Baudin, Dana M. Hartl, and Joanne Guerlain

Subjects
Oncology, Cancer Research, medicine.medical_specialty, medicine.diagnostic_test, business.industry, medicine.medical_treatment, Thyroid, Thyroid Lobectomy, Neck dissection, Hematology, General Medicine, Disease, Scintigraphy, medicine.disease, Thyroid carcinoma, medicine.anatomical_structure, Quality of life, Internal medicine, medicine, Radiology, Nuclear Medicine and imaging, business, Thyroid cancer
Abstract

Thyroid cancer runs the gamut from indolent micropapillary carcinoma to highly aggressive metastatic disease. Today, using prognostic algorithms, treatment and follow-up can be tailored to each patient in order to decrease overtreatment and over-medicalization of indolent disease. Active surveillance of papillary thyroid carcinoma less than 1cm avoids surgery and thyroid hormone replacement in a large proportion of patient whose tumors remain stable for years. Total thyroidectomy, once a dogma in the treatment of all thyroid cancer, is being supplanted by thyroid lobectomy for low-risk cancers, thereby decreasing the surgical risks involved and improving patients' quality of life. Indications for prophylactic central neck dissection, once mandatory, are now being adapted to the risk of cancer recurrence. Radioactive iodine therapy, also previously mandatory for all, is now only employed according to risk factors and expected outcomes. Follow-up is also being tailored to risk factors for recurrence, with less frequent visits and less use of ultrasound and scintigraphy. For more advanced disease, molecular therapies tailored to somatic mutations are opening opportunities for redifferentiation of aggressive tumors which become amenable to radioactive iodine therapy which carries fewer side effects than other systemic therapies. These advances in the management of thyroid cancer with a personalized approach and de-escalation of treatment and follow-up are improving the way we treat thyroid cancer, avoiding overtreatment and improving patients' quality of life.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results